PPARG and ovarian carcinoma: More recently, Yang et al. [40] demonstrated that troglitazone (10–30 μM) inhibited migration and invasiveness of a human ovarian carcinoma ES-2 cells but that PPARγ knockdown by siRNA did not reverse this effect underscoring the idea that the PPARγ agonists may reduce cancer cell invasion by a receptor-independent mechanism.